T-THERAPEUTICS LIMITED

• ⚠

  Material uncertainty over going concern

  While the need for investor majority approval to be obtained and the additional funding to be secured creates a material uncertainty which may cast significant doubt over the ability of the group and company to continue as a going concern, however, the directors expect the final milestone amount to be received and are confident that the additional funding can be secured so have concluded that the use of the going concern basis of accounting in the preparation of the financial statements remains appropriate.

• ◆

  1 PSC ceased in last 24 months

  Significant control changed hands — see the Ownership section.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Consolidated group

Auditor

RSM UK Audit LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“While the need for investor majority approval to be obtained and the additional funding to be secured creates a material uncertainty which may cast significant doubt over the ability of the group and company to continue as a going concern, however, the directors expect the final milestone amount to be received and are confident that the additional funding can be secured so have concluded that the use of the going concern basis of accounting in the preparation of the financial statements remains appropriate.”

Group structure

1. T-THERAPEUTICS LIMITED · parent
   1. T-Therapeutics Taiwan Co Ltd 100% · Taiwan · Research and development

Significant events

• “On 31 January 2024 T-Therapeutics Ltd (the Company) acquired the entire share capital of T-Therapeutics Taiwan Co., Ltd (formerly Kymab Biotechnology Co., Ltd) a company based In Taiwan. This enabled the Company to set up research facilities concentrating on research into autoimmune diseases. The increase in the headcount this year is largely due to the acquisition of the Taiwanese company.”
• “In November 2023 the Group agreed to lease one floor of a new building on Granta Park, 'One Granta', on a shell and core basis and the lease was completed in September 2024.”
• “On 14 May 2025, £4m of the Tranche 3 Series A investment became payable. On the same date, 257,142,888 new Series A shares were issued as bonus shares. The remaining £14.2m of the Tranche 3 Series A investment is due on 24 July 2025, subject to investor majority being obtained.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

20

last 12 months

Capital events

8

last 24 months

Officers appointed

3

last 12 months

Officers resigned

2

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  —

  Not reported

• Cash

  +54.4%

  £5,651,831 → £8,725,881

• Net assets

  +41.4%

  £9,304,794 → £13,159,036

• Employees

  +109.1%

  33 → 69

• Operating profit

  -109.7%

  -£7,402,966 → -£15,521,090

• Profit before tax

  -112.3%

  -£7,072,280 → -£15,016,801

• Wages

  +139.8%

  £2,608,562 → £6,256,128

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers